AI-generated analysis. Always verify with the original filing.
Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC on March 19, 2026, enabling the offer and sale of up to $100,000,000 of its common stock through at-the-market offerings. Net proceeds will fund general corporate purposes, including research and development, clinical trials, capital expenditures, and working capital.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 19, 2026, Genelux Corporation (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with T
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Sales Agreement, dated as of March 19, 2026, by and between Genelux Corporation
Material Agreement